November 2014 Edition Vol.11, Issue 11

Market Conditions that Impact New Oncology Product Uptake

Market Conditions that Impact New Oncology Product Uptake (continued)

How will Physicians Perceive the Future on Product Launches?

To better understand the perceptions of US oncologists on how product launches will impact cancer treatment in the future, Ipsos Healthcare fielded a small survey (n=86) to the Ipsos Healthcare US Oncology Monitor Panel (a 5-minute perceptual online survey), seeking to gauge views.

Tumors Likely to See Advances in Treatment over the Next Few Years

When asked in which tumor type the physicians foresee the greatest advances, over half of respondents (53%) stated that lung cancer is the main tumor likely to see advances in treatment over the next few years.  Thirty-eight percent were excited about the advances in breast cancer treatment, while 34% indicated lymphoma as a tumor with treatment progress in coming years. 

The Most Anticipated Drug Classes

When asked about the most anticipated drug classes, immune checkpoint inhibitors and PI3K inhibitors (each with over 85 active trials), and BTK inhibitors (with over 20 active trials) were mentioned most often.

The New Drugs with Greatest Potential

According to the survey, the following 3 drugs were said to have the greatest future potential.

Nivolumab (BMS): Nivolumab works by blocking a protein called programmed cell death 1 (PD-1). Drugs which inhibit PD-1 may be able to treat a variety of cancers. Bristol-Myers Squibb is currently enrolling participants in clinical trials for lung cancer, melanoma, renal cell carcinoma, and other advanced or metastatic solid tumors. Nivolumab was launched in Japan in July 2014 making it the first PD-1 to market in that country.


Idelalisib (Gilead): Idelalisib is a targeted oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that is critical for the activation, proliferation and survival of B lymphocytes. It was in trials for iNHL and CLL at the time the survey was fielded, and has since been approved for CLL.

Ibrutinib (Janssen/Pharmacyclics): Ibrutinib is a first in class oral tyrosine kinase inhibitor and is used to treat CLL and a type of NHL known as mantle cell lymphoma. Since the survey was fielded, its approval has been expanded to CLL patients with 17p deletions. It is also being studied for use against other types of leukemia, lymphoma, and other cancers.

New Oncology Research & Product Development

Lastly, when cancer-treating physicians were asked which pharmaceutical companies they perceive to be leaders in cancer, Genentech was mentioned by half of the physicians, followed by Novartis with a little over a third of responses, and Pfizer and Amgen each with around 25%.

In Conclusion

Despite high phase II and phase III trial failure rates, the oncology development landscape is still crowded, with nearly 50 FDA approvals in 5 years. Many of these new compounds have been approved on the basis of showing significant efficacy in niche indications; companion diagnostics are a big part of the approval process and have helped propel shares provided testing rates don’t lag behind. Several recent examples of new entrants targeting the same specific subset of patients have launched in niche indications, but the being first to market is often crucial for maximizing peak share.

Although many new players have entered the oncology space with recently launched products and/or promising pipeline products, and although some of these products have generated a lot of excitement among our panel doctors, those same doctors still largely regard the traditional players as being the leaders in oncology.

Clearly, success in the oncology space is highly sought after for pharmaceutical companies, and it is still possible to see very quick uptake—albeit often in small patient segments—despite the ever-increasing competition. We have discussed several examples of products that have successfully negotiated the challenges facing any new entrant in this space and one thing is clear: companies must continue to be innovative and to re-think launch strategies, especially if they seek to be recognized by physicians as one of the top oncology companies in the industry.

____________________________________________________________________________________

Resources

  1. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. Accessed November 8, 2014.
     
  2. Genetic Engineering & Biotechnology News. Top 10 Clinical Trial Failures of 2013. http://www.genengnews.com/insight-and-intelligence/top-10-clinical-trial-failures-of-2013/77900029/. Accessed November 8, 2014.

____________________________________________________________________________________

About the Contributor

Jackie Ilacqua is Global Head of Syndicated Services and President of Global Oncology of Ipsos Healthcare, leading the company’s syndicated and custom oncology business around the globe. She is also a member of the Ipsos Healthcare Board.  She can be reached at 201-574-8079 or jackie.ilacqua@ipsos.com.

Ipsos Healthcare, operating in 40 countries around the world, is a global specialized practice focusing on research in the pharmaceutical, bio-tech and medical device markets.  Ipsos Healthcare’s Syndicated Services include the market-leading Global Oncology Monitor and Global Therapy Monitors, which, together, comprise the industry’s largest portfolio of syndicated patient chart audit data. The Syndicated Services portfolio also includes oncology molecular diagnostics, oncology social listening, disease-specific ethnography studies and a suite of commercial strategy offerings.

Pages: 1 2 3

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.